tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

EVMN Stock Latest News

Evommune price target raised to $55 from $40 at Evercore ISI
The FlyEvommune price target raised to $55 from $40 at Evercore ISI
2d ago
EVMN
Evommune: Robust IL-18 Phase 2a Atopic Dermatitis Data Underpins Buy Rating and Higher $55 Target with Additional Indication Upside
PremiumRatings
Evommune: Robust IL-18 Phase 2a Atopic Dermatitis Data Underpins Buy Rating and Higher $55 Target with Additional Indication Upside
2d ago
EVMN
Evommune price target raised to $65 from $35 at H.C. Wainwright
PremiumThe Fly
Evommune price target raised to $65 from $35 at H.C. Wainwright
2d ago
EVMN
Midday Fly By: Coca-Cola reports Q4 beat, BP suspends buyback
PremiumThe Fly
Midday Fly By: Coca-Cola reports Q4 beat, BP suspends buyback
2d ago
U
BP
Evommune Advances EVO301 After Positive Phase 2a Results
PremiumCompany Announcements
Evommune Advances EVO301 After Positive Phase 2a Results
2d ago
8K
EVMN
Evommune jumps 67% to $28.13 after atopic dermatitis data
PremiumThe FlyEvommune jumps 67% to $28.13 after atopic dermatitis data
2d ago
EVMN
Evommune reports EVO301 trial met primary endpoint
Premium
The Fly
Evommune reports EVO301 trial met primary endpoint
2d ago
EVMN
Evommune management to meet with Oppenheimer
Premium
The Fly
Evommune management to meet with Oppenheimer
15d ago
EVMN
3 ‘Strong Buy’ Stocks to Buy Now, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Now, According to Top Analysts
18d ago
ALK
EVMN
Evommune initiated with an Outperform at Oppenheimer
PremiumThe Fly
Evommune initiated with an Outperform at Oppenheimer
21d ago
EVMN
Evommune: Buy Rating Driven by Upcoming Phase II Readouts and Broad Inflammatory Disease Pipeline Potential
PremiumRatings
Evommune: Buy Rating Driven by Upcoming Phase II Readouts and Broad Inflammatory Disease Pipeline Potential
1M ago
EVMN
Evommune initiated with a Strong Buy at Raymond James
PremiumThe Fly
Evommune initiated with a Strong Buy at Raymond James
1M ago
EVMN
Evommune initiated with a Strong Buy at Raymond James
PremiumThe FlyEvommune initiated with a Strong Buy at Raymond James
1M ago
EVMN
Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch
Premium
Company Announcements
Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch
1M ago
EVMN
Evommune participates in a conference call with William Blair
Premium
The Fly
Evommune participates in a conference call with William Blair
1M ago
EVMN
Evommune initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Evommune initiated with a Buy at H.C. Wainwright
1M ago
EVMN
3 ‘Strong Buy’ Stocks to Buy Now,12/30/2025, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Now,12/30/2025, According to Top Analysts
1M ago
VIR
EVMN
Evommune: Multiple 2026 Phase II Readouts and Novel Immunology Mechanisms Drive Compelling Buy-Rated Risk‑Reward
PremiumRatings
Evommune: Multiple 2026 Phase II Readouts and Novel Immunology Mechanisms Drive Compelling Buy-Rated Risk‑Reward
1M ago
EVMN
Buy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial Potential
PremiumRatings
Buy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial Potential
2M ago
EVMN
Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating
PremiumRatingsEvommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating
2M ago
EVMN
Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%
Premium
The Fly
Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%
2M ago
NX
RH
Evommune reports Q3 EPS ($8.07) vs ($10.47) last year
Premium
The Fly
Evommune reports Q3 EPS ($8.07) vs ($10.47) last year
2M ago
EVMN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >